Cargando…
A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)
PURPOSE: This study was performed to compare the efficacies and acute toxicities in weekly- and three weekly- cisplatin based concurrent chemoradiotherapy (CCRT) for advanced HNC patients. RESULTS: 779 patients of 10 studies were eligible. No difference in the 2-, 3-year OS or 1-, 2-year LRFS was ob...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342545/ https://www.ncbi.nlm.nih.gov/pubmed/27602493 http://dx.doi.org/10.18632/oncotarget.11824 |
_version_ | 1782513205120073728 |
---|---|
author | Guan, Jian Zhang, Yue Li, Qinyang Zhang, Yaowei Li, Lu Chen, Min Xiao, Nanjie Chen, Longhua |
author_facet | Guan, Jian Zhang, Yue Li, Qinyang Zhang, Yaowei Li, Lu Chen, Min Xiao, Nanjie Chen, Longhua |
author_sort | Guan, Jian |
collection | PubMed |
description | PURPOSE: This study was performed to compare the efficacies and acute toxicities in weekly- and three weekly- cisplatin based concurrent chemoradiotherapy (CCRT) for advanced HNC patients. RESULTS: 779 patients of 10 studies were eligible. No difference in the 2-, 3-year OS or 1-, 2-year LRFS was observed, whereas patients in three weekly CCRT arm tended to have a better 5-year OS (HR=1.79, 95%C 0.97-3.31, p=0.06). Weekly arm seemed to show less gastrointestinal toxicities (RR=0.59, 95%CI 0.34-1.02, p=0.06), but similar hematologic toxicity compared to three weekly arm. Subgroup analysis displayed more grade ≥3 mucositis (RR=1.72, p=0.01), and more chemotherapy related delay/interrupt (RR=2.68, p<0.0001) in weekly arm for non-nasopharynx carcinoma (non-NPC) HNC. METHODS: We conducted the meta-analysis by searching PubMed, MEDLINE, ScienceDirect, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases. The primary endpoint was overall survival (OS) with secondary endpoints locoregional recurrence-free survival (LRFS) and grade≥3 acute adverse events. RevMan 5.2 was used to perform statistical analyses. CONCLUSIONS: Three weekly cisplatin-based CCRT might achieve a higher long-term OS with no significant difference in a shorter OS and LRFS. Weekly arm was associated with less gastrointestinal toxicities but more grade≥3 mucositis and chemotherapy related delay/interrupt. Large randomized trials were urgent to further define superiority of these two regimens. |
format | Online Article Text |
id | pubmed-5342545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53425452017-03-24 A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) Guan, Jian Zhang, Yue Li, Qinyang Zhang, Yaowei Li, Lu Chen, Min Xiao, Nanjie Chen, Longhua Oncotarget Research Paper PURPOSE: This study was performed to compare the efficacies and acute toxicities in weekly- and three weekly- cisplatin based concurrent chemoradiotherapy (CCRT) for advanced HNC patients. RESULTS: 779 patients of 10 studies were eligible. No difference in the 2-, 3-year OS or 1-, 2-year LRFS was observed, whereas patients in three weekly CCRT arm tended to have a better 5-year OS (HR=1.79, 95%C 0.97-3.31, p=0.06). Weekly arm seemed to show less gastrointestinal toxicities (RR=0.59, 95%CI 0.34-1.02, p=0.06), but similar hematologic toxicity compared to three weekly arm. Subgroup analysis displayed more grade ≥3 mucositis (RR=1.72, p=0.01), and more chemotherapy related delay/interrupt (RR=2.68, p<0.0001) in weekly arm for non-nasopharynx carcinoma (non-NPC) HNC. METHODS: We conducted the meta-analysis by searching PubMed, MEDLINE, ScienceDirect, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases. The primary endpoint was overall survival (OS) with secondary endpoints locoregional recurrence-free survival (LRFS) and grade≥3 acute adverse events. RevMan 5.2 was used to perform statistical analyses. CONCLUSIONS: Three weekly cisplatin-based CCRT might achieve a higher long-term OS with no significant difference in a shorter OS and LRFS. Weekly arm was associated with less gastrointestinal toxicities but more grade≥3 mucositis and chemotherapy related delay/interrupt. Large randomized trials were urgent to further define superiority of these two regimens. Impact Journals LLC 2016-09-02 /pmc/articles/PMC5342545/ /pubmed/27602493 http://dx.doi.org/10.18632/oncotarget.11824 Text en Copyright: © 2016 Guan et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Guan, Jian Zhang, Yue Li, Qinyang Zhang, Yaowei Li, Lu Chen, Min Xiao, Nanjie Chen, Longhua A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) |
title | A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) |
title_full | A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) |
title_fullStr | A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) |
title_full_unstemmed | A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) |
title_short | A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC) |
title_sort | meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (crt) for advanced head and neck cancer (hnc) |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342545/ https://www.ncbi.nlm.nih.gov/pubmed/27602493 http://dx.doi.org/10.18632/oncotarget.11824 |
work_keys_str_mv | AT guanjian ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT zhangyue ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT liqinyang ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT zhangyaowei ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT lilu ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT chenmin ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT xiaonanjie ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT chenlonghua ametaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT guanjian metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT zhangyue metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT liqinyang metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT zhangyaowei metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT lilu metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT chenmin metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT xiaonanjie metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc AT chenlonghua metaanalysisofweeklycisplatinversusthreeweeklycisplatinchemotherapyplusconcurrentradiotherapycrtforadvancedheadandneckcancerhnc |